Stay updated on IBI310 Combo vs Sorafenib in HCC Clinical Trial
Sign up to get notified when there's something new on the IBI310 Combo vs Sorafenib in HCC Clinical Trial page.

Latest updates to the IBI310 Combo vs Sorafenib in HCC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe Record History shows the latest revision updated to v3.5.3, replacing the previous v3.5.2. This indicates a new version of the study record has been published.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision: v3.5.2 was added to the record history, and revision v3.5.0 was removed.SummaryDifference0.1%

- Check46 days agoChange DetectedRevision v3.5.0 adds Study Status, Contacts/Locations, and Study Design and marks the study as Completed; the prior update removed the Recruiting status and sponsor Innovent Biologics (Suzhou) Co. Ltd.SummaryDifference2%

- Check60 days agoChange DetectedThe record history now includes revision v3.4.3 and removes v3.4.2 from the history.SummaryDifference0.1%

- Check89 days agoChange DetectedThe history page adds Revision: v3.4.2 and removes the government funding notice and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check96 days agoChange DetectedAdded a site-wide funding-status banner noting potential delays and that the NIH Clinical Center is open, and updated the page revision to v3.4.1 from v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

Stay in the know with updates to IBI310 Combo vs Sorafenib in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IBI310 Combo vs Sorafenib in HCC Clinical Trial page.